Logo image of RAPP

RAPPORT THERAPEUTICS INC (RAPP) Stock Fundamental Analysis

NASDAQ:RAPP - Nasdaq - US75383L1026 - Common Stock - Currency: USD

12.66  +0.33 (+2.68%)

After market: 12.66 0 (0%)

Fundamental Rating

3

Overall RAPP gets a fundamental rating of 3 out of 10. We evaluated RAPP against 195 industry peers in the Pharmaceuticals industry. RAPP has a great financial health rating, but its profitability evaluates not so good. RAPP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RAPP has reported negative net income.
RAPP had a negative operating cash flow in the past year.
RAPP Yearly Net Income VS EBIT VS OCF VS FCFRAPP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -26.49%, RAPP perfoms like the industry average, outperforming 56.92% of the companies in the same industry.
With a decent Return On Equity value of -27.97%, RAPP is doing good in the industry, outperforming 64.62% of the companies in the same industry.
Industry RankSector Rank
ROA -26.49%
ROE -27.97%
ROIC N/A
ROA(3y)-27.02%
ROA(5y)N/A
ROE(3y)-35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RAPP Yearly ROA, ROE, ROICRAPP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

RAPP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPP Yearly Profit, Operating, Gross MarginsRAPP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for RAPP has been increased compared to 1 year ago.
There is no outstanding debt for RAPP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RAPP Yearly Shares OutstandingRAPP Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
RAPP Yearly Total Debt VS Total AssetsRAPP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 16.28 indicates that RAPP is not in any danger for bankruptcy at the moment.
The Altman-Z score of RAPP (16.28) is better than 91.28% of its industry peers.
There is no outstanding debt for RAPP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.28
ROIC/WACCN/A
WACCN/A
RAPP Yearly LT Debt VS Equity VS FCFRAPP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

RAPP has a Current Ratio of 31.02. This indicates that RAPP is financially healthy and has no problem in meeting its short term obligations.
RAPP has a Current ratio of 31.02. This is amongst the best in the industry. RAPP outperforms 97.95% of its industry peers.
A Quick Ratio of 31.02 indicates that RAPP has no problem at all paying its short term obligations.
RAPP's Quick ratio of 31.02 is amongst the best of the industry. RAPP outperforms 97.95% of its industry peers.
Industry RankSector Rank
Current Ratio 31.02
Quick Ratio 31.02
RAPP Yearly Current Assets VS Current LiabilitesRAPP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

RAPP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -271.00%.
EPS 1Y (TTM)-271%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -9.65% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.22%
EPS Next 2Y-7.95%
EPS Next 3Y-9.65%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPP Yearly EPS VS EstimatesRAPP Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RAPP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RAPP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPP Price Earnings VS Forward Price EarningsRAPP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPP Per share dataRAPP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A cheap valuation may be justified as RAPP's earnings are expected to decrease with -9.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.95%
EPS Next 3Y-9.65%

More info and screens

0

5. Dividend

5.1 Amount

RAPP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPPORT THERAPEUTICS INC

NASDAQ:RAPP (6/6/2025, 8:22:12 PM)

After market: 12.66 0 (0%)

12.66

+0.33 (+2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners119.17%
Inst Owner Change4.39%
Ins Owners6.54%
Ins Owner Change0.05%
Market Cap462.09M
Analysts85.45
Price Target35.7 (181.99%)
Short Float %7.22%
Short Ratio12.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.43%
Min EPS beat(2)10.59%
Max EPS beat(2)12.28%
EPS beat(4)3
Avg EPS beat(4)-27.26%
Min EPS beat(4)-146.79%
Max EPS beat(4)14.9%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.25%
EPS NQ rev (1m)3.85%
EPS NQ rev (3m)-4.83%
EPS NY rev (1m)5.51%
EPS NY rev (3m)-0.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.62
P/tB 1.62
EV/EBITDA N/A
EPS(TTM)-3.45
EYN/A
EPS(NY)-4.4
Fwd EYN/A
FCF(TTM)-1.88
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0
BVpS7.84
TBVpS7.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.49%
ROE -27.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.02%
ROA(5y)N/A
ROE(3y)-35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 31.02
Quick Ratio 31.02
Altman-Z 16.28
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1223.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-271%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.25%
EPS Next Y11.22%
EPS Next 2Y-7.95%
EPS Next 3Y-9.65%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-130.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-60.65%
EBIT Next 3Y-45.73%
EBIT Next 5YN/A
FCF growth 1Y-135.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.74%
OCF growth 3YN/A
OCF growth 5YN/A